Artivion Inc (AORT)

Currency in USD
28.39
+2.08(+7.91%)
Closed·
28.390.00(0.00%)
·
Advertisement
AORT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
26.2628.66
52 wk Range
19.1648.25
Key Statistics
Prev. Close
28.39
Open
26.26
Day's Range
26.26-28.66
52 wk Range
19.16-48.25
Volume
884.61K
Average Volume (3m)
754K
1-Year Change
-35.2566%
Book Value / Share
9.18
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AORT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
42.03
Upside
+48.03%
Members' Sentiments
Bearish
Bullish
ProTips
Liquid assets exceed short term obligations

Artivion Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 42.03
(+48.03% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Canaccord
Buy39.00+37.37%36.00Maintain07/08/2026
Citizens
Buy48.00+69.07%-Maintain21/07/2026
Needham
Buy44.00+54.98%-Maintain20/07/2026
Canaccord
Buy36.00+26.81%-Maintain29/06/2026
Canaccord
Buy36.00+26.81%-Maintain16/06/2026

Artivion Inc Earnings Call Summary for Q2/2026

  • Q2 revenue rose 9% constant-currency to $125.8M, beating $120.06M forecast; stent grafts up 12%, On-X valves up 18% year-over-year.
  • Artivion received FDA PMA approval for AMDS in late June; completed Endospan acquisition with NEXUS U.S. launch planned for January 2027.
  • Adjusted EBITDA margin compressed 90bps to 21% on higher R&D spending and acquisition costs; free cash flow negative $12M versus positive $11.7M prior year.
  • Full-year 2026 guidance unchanged at 7-11% revenue growth ($480-496M) and $92-99M adjusted EBITDA despite Q2 beat due to timing factors.
  • Management expects 2027 to be 'meaningfully free cash flow positive' with NEXUS revenue beginning January; net leverage stands at 3.1x at quarter-end.
Last Updated: 06/08/2026, 22:38
Read Full Transcript

Earnings

Latest Release
06/08/2026
EPS / Forecast
-0.28 / 0.01
Revenue / Forecast
125.76M / 120.06M
EPS Revisions
Last 90 days

Compare AORT to Peers and Sector

Metrics to compare
AORT
Peers
Sector
Relationship
P/E Ratio
−433.8x−1.3x−0.4x
PEG Ratio
−4.920.000.00
Price/Book
3.1x2.1x2.6x
Price / LTM Sales
2.9x1.9x3.1x
Upside (Analyst Target)
53.7%10.0%47.5%
Fair Value Upside
Unlock29.5%5.9%Unlock

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system; E-xtra Design Engineering, a range of stent graft systems for the treatment of aortic vascular diseases, such as TAAA and Artivex; E-nside, a multibranch stent graft system; E-tegra, an AAA stent graft system; E-ventus BX and Tuva BX balloon-expandable peripheral stent grafts; and E-liac, a stent graft used to treat aneurysmal iliac arteries. In addition, the company offers synthetic vascular grafts that are used in open aortic and peripheral vascular surgical procedures; BioGlue, a surgical sealant; CryoValve SG pulmonary heart valve; CryoPatch SG pulmonary cardiac patch; SynerGraft, a decellularization technology; vascular preservation services; and PhotoFix, a bovine pericardial patch fixated. It markets its products and preservation services primarily to physicians through a direct sales team to hospitals and other healthcare facilities. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
22.49M46.32%591.59M
Other Institutional Investors
24.17M49.80%636.03M
Public Companies & Retail Investors
1.88M3.88%49.56M
Total
48.54M100.00%1.28B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.13.34%6,474,854170,353
iShares Trust - iShares Core S&P Small-Cap ETF5.36%2,601,77368,453

People Also Watch

5.740
TLSI
+2.87%
1.460
STXS
+1.39%
4.32
MDXG
+1.17%
2.2700
VGZ
+1.79%

FAQ

What Is the Artivion (NYSE: AORT) Share Price Today?

The Artivion stock price today is 28.39 USD.

What Stock Exchange Does Artivion (AORT) Trade On?

Artivion is listed and trades on the New York Stock Exchange.

What Is the Ticker (Stock Symbol) for Artivion?

The stock symbol (also called a 'ticker') for Artivion is "AORT."

What Is the Current Artivion Market Capitalisation?

As of today, Artivion (NYSE: AORT) market cap is 1.38B USD.

What Is Artivion's (AORT) Earnings Per Share (TTM)?

The Artivion EPS is currently -0.07 (Trailing Twelve Months).

When Is the Next Artivion Earnings Date?

Artivion's next earnings report will be released on 29/10/2026.

Is AORT a Buy or Sell From a Technical Analyst Perspective?

Based on today's Artivion moving averages and other technical indicators, the daily buy/sell signal for AORT stock is Strong Buy.

How Many Times Has Artivion Stock Split?

Artivion has split 2 times. (See the AORT stock split history page for full effective split date and price information.)

How Many Employees Does Artivion Have?

Artivion has 1800 employees, based on their latest Companies House report.

What is the current trading status of Artivion (NYSE: AORT)?

As of 12/08/2026, Artivion (AORT) is trading at a share price of 28.39 USD, with a previous close of 28.39 USD. The stock has fluctuated within a day range of 26.26 USD to 28.66 USD, while its 52-week range spans from 19.16 USD to 48.25 USD.

What Is Artivion (AORT) Price Target According to Analysts?

The average 12-month price target for Artivion is 42.03 USD, with a high estimate of 48 USD and a low estimate of 38 USD. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +48.03% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.